Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347412 · ClinicalTrials.gov registry record · Phase 3
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
A Phase 3 study, sponsored by Cellectar Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 903
- Enrollment target
NCT00347412 is a Phase 3 study that has completed, run by Cellectar Biosciences. The registered enrollment target is 903 participants.
The verdict
NCT00347412, a Phase 3 study, has completed, sponsored by Cellectar Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 903 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC). Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemotherapy alone; and in two Phase 2 trials done in Russian patients, at the end of one year, patients treated with NOV-002 with chemotherapy had a better survival rate than patients who did not receive NOV-002 with their chemotherapy.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG NOV-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 903 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00347412
The ClinicalTrials.gov registry entry for NCT00347412 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 903 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellectar Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00347412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00347412 about?
NCT00347412 is a clinical study titled "Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer". The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC). Earlier clinical trials in N...
What is the current status of trial NCT00347412?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 903 participants. The study started on 2006-11. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00347412?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), NOV-002 (DRUG).
Who is sponsoring clinical trial NCT00347412?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.